180 related articles for article (PubMed ID: 28043761)
1. The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
Mariette X; Alten R; Nüßlein HG; Galeazzi M; Lorenz HM; Cantagrel A; Chartier M; Poncet C; Rauch C; Le Bars M
Joint Bone Spine; 2017 Oct; 84(5):571-576. PubMed ID: 28043761
[TBL] [Abstract][Full Text] [Related]
2. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).
Iannone F; Courvoisier DS; Gottenberg JE; Hernandez MV; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Choquette D; Finckh A
Clin Rheumatol; 2017 Apr; 36(4):773-779. PubMed ID: 27966068
[TBL] [Abstract][Full Text] [Related]
3. Two-year abatacept retention rate in clinical practice in the French ACTION cohort.
Mariette X; Schaeverbeke T; Gaudin P; Chartier M; Heitzmann J; Vannier-Moreau V; Hilliquin P; Cantagrel A
Joint Bone Spine; 2019 Nov; 86(6):753-759. PubMed ID: 31352138
[TBL] [Abstract][Full Text] [Related]
4. Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
D'Agostino MA; Alten R; Mysler E; Le Bars M; Ye J; Murthy B; Heitzmann J; Vadanici R; Ferraccioli G
Clin Rheumatol; 2017 Dec; 36(12):2655-2665. PubMed ID: 28822046
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
BMC Musculoskelet Disord; 2015 Jul; 16():176. PubMed ID: 26228643
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Boumpas D; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Rainer F; Pavelka K; Chartier M; Poncet C; Rauch C; Bars ML
BMC Musculoskelet Disord; 2014 Jan; 15():14. PubMed ID: 24410774
[TBL] [Abstract][Full Text] [Related]
7. Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a
McInnes IB; Ferraccioli G; D'Agostino MA; Le Bars M; Banerjee S; Ahmad HA; Elbez Y; Mease PJ
RMD Open; 2019; 5(1):e000934. PubMed ID: 31245054
[TBL] [Abstract][Full Text] [Related]
8. Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
Alten R; Mariette X; Lorenz HM; Nüßlein H; Galeazzi M; Navarro F; Chartier M; Heitzmann J; Poncet C; Rauch C; Le Bars M
Clin Rheumatol; 2019 May; 38(5):1413-1424. PubMed ID: 30790095
[TBL] [Abstract][Full Text] [Related]
9. Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.
Alten R; Feist E; Lorenz HM; Nüßlein H; Voll RE; Chartier M; Elbez Y; Rauch C
Clin Rheumatol; 2019 Nov; 38(11):3049-3059. PubMed ID: 31300979
[TBL] [Abstract][Full Text] [Related]
10. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
Kim SK; Choe JY; Park SH; Lee H
Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
[TBL] [Abstract][Full Text] [Related]
11. Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study.
Schulman E; Bartlett SJ; Schieir O; Andersen KM; Boire G; Pope JE; Hitchon C; Jamal S; Thorne JC; Tin D; Keystone EC; Haraoui B; Goodman SM; Bykerk VP;
Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1185-1191. PubMed ID: 29193840
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Peichl P; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
Clin Exp Rheumatol; 2016; 34(3):489-99. PubMed ID: 26966919
[TBL] [Abstract][Full Text] [Related]
13. Body mass index as a driver of selection of biologic therapy in rheumatoid arthritis. Results from the US-CLARA study.
Di Carlo M; Salaffi F; Gremese E; Iannone F; Lapadula G; Ferraccioli G;
Eur J Intern Med; 2019 Aug; 66():57-61. PubMed ID: 31113709
[TBL] [Abstract][Full Text] [Related]
14. Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.
Alten R; Mariette X; Lorenz HM; Galeazzi M; Cantagrel A; Nüßlein HG; Chartier M; Elbez Y; Rauch C; Le Bars M
RMD Open; 2017; 3(2):e000538. PubMed ID: 29435360
[TBL] [Abstract][Full Text] [Related]
15. Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study.
Westhovens R; Connolly SE; Margaux J; Vanden Berghe M; Maertens M; Van den Berghe M; Elbez Y; Chartier M; Baeke F; Robert S; Malaise M
Rheumatol Int; 2020 Sep; 40(9):1409-1421. PubMed ID: 32556473
[TBL] [Abstract][Full Text] [Related]
16. High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis.
Lee JS; Ahmad H; Shim SC; Bae SC; Song YW; Lee EY
Patient; 2019 Jun; 12(3):319-326. PubMed ID: 30484084
[TBL] [Abstract][Full Text] [Related]
17. Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study.
Peichl P; Alten R; Galeazzi M; Lorenz HM; Nüßlein H; Navarro F; Elbez Y; Chartier M; Hackl R; Rauch C; Connolly SE
Wien Med Wochenschr; 2020 Apr; 170(5-6):132-140. PubMed ID: 31654156
[TBL] [Abstract][Full Text] [Related]
18. On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.
Bykerk VP; Burmester GR; Combe BG; Furst DE; Huizinga TWJ; Ahmad HA; Emery P
Rheumatol Int; 2018 Dec; 38(12):2225-2231. PubMed ID: 30341453
[TBL] [Abstract][Full Text] [Related]
19. Body mass index and response to abatacept in rheumatoid arthritis.
Gardette A; Ottaviani S; Sellam J; Berenbaum F; Lioté F; Fautrel B; Palazzo E; Meyer A; Sibilia J; Dieudé P
Eur J Clin Invest; 2016 Dec; 46(12):1048-1052. PubMed ID: 27736006
[TBL] [Abstract][Full Text] [Related]
20. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
Smolen JS; Wollenhaupt J; Gomez-Reino JJ; Grassi W; Gaillez C; Poncet C; Le Bars M; Westhovens R
Arthritis Res Ther; 2015 Jun; 17(1):157. PubMed ID: 26063454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]